GIOSTAR leaders recently wrote on the potential benefits of stem cells in combating COVID-19. Published in Stem Cell Reviews and Reports, the review was written by Drs. Anand Srivastava, Prabhat Soni, Diana Esquivel, Rangnath Mishra, Rajasekar Seetharaman, and Anjum Mahmood
GIOSTAR recently treated a patient suffering from COVID-19 with stem cells. He experienced considerable improvement following this procedure. A placebo-controlled, double-blind study would be needed to better understand the measurable outcome of stem cell treatment for COVID-19.
GIOSTAR Chairman and Co-Founder Dr. Anand Srivastava recently spoke with Healthcare Weekly about stem cells, COVID-19, and numerous other topics.
Drs. Anand Srivastava and Prabhat Soni write in a medical journal on the potential benefits of stem cells in fighting against COVID-19. GIOSTAR recently received FDA Approval Under Compassionate Use to treat COVID-19 patients under compassionate use.
GIOSTAR Co-Founder Dr. Anand Srivastava discusses his ground-breaking research on creating red blood cells from stem cells. This innovation has the potential to eradicate diseases worldwide by solving three central problems with blood transfusion.
IMPORTANT! All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice. Statements made on this website have not been evaluated by the Food and Drug Administration. The information contained herein is not intended to diagnose, treat, cure or prevent any disease.
